Soleno only has one indication, their first Phase 3 trial (C601) did not meet primary endpoint, then did another one (C602).
Soleno market cap was US$2.25B before the FDA approval, now its share price rises 32.73% after-market, its market cap is US$3B.
NEU's market cap is US$0.96B.
- With US$220m cash,
- Approved DAYBUE, partnered with Acadia, receiving annual royalties and milestone payments,
- Phase 3 for PMS anticipated to start mid 2025, PMS addressable market size is 2 to 3 times of DAYBUE;
- Two successful concluded Phase 2 trials;
- New indications.
Maybe JP should consider to be dual listing in Nasdaq?
![]()
![]()
- Forums
- ASX - By Stock
- NEU
- Ann: Prader-Willi syndrome IND for NNZ-2591 approved by FDA
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.31%
!
$17.78

Ann: Prader-Willi syndrome IND for NNZ-2591 approved by FDA, page-26
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$17.78 |
Change
0.230(1.31%) |
Mkt cap ! $2.240B |
Open | High | Low | Value | Volume |
$17.83 | $17.99 | $17.35 | $16.12M | 911.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 11000 | $17.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.80 | 10070 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11000 | 17.400 |
4 | 4289 | 17.300 |
1 | 170 | 17.250 |
1 | 300 | 17.100 |
1 | 58 | 17.060 |
Price($) | Vol. | No. |
---|---|---|
17.800 | 10070 | 2 |
17.820 | 202 | 2 |
17.870 | 2300 | 2 |
17.890 | 8773 | 3 |
17.940 | 566 | 1 |
Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |